DIA Europe 2025 to Address EU Regulatory Reforms and How to Advance Global Healthcare Harmonization
Experts will explore AI-driven healthcare innovation and strategies to enhance patient engagement
DIA, a global non-profit organization of life sciences professionals, will unite stakeholders from across Europe and the world to discuss increasing efficiencies in healthcare systems, the future of international collaboration, and recent changes to regulatory frameworks at DIA Europe 2025 from March 18-20 in Basel.
The continent's premier neutral healthcare conference, DIA Europe 2025 will host more than 300 speakers from over 150 organizations and present over 100 topics across 10 content tracks — including two, clinical trials innovation and global insights, that have been reworked from previous years to better reflect current needs and challenges. These discussions will shape policies that strengthen pharmaceutical development and patient care, with sessions examining environmental impact, regulatory digitalization, artificial intelligence (AI), and critical reforms under the new EU pharmaceutical legislation.
Representatives from the European Medicines Agency (EMA), the European Commission, national competent authorities, notified bodies, academia, health technology assessment bodies, patient advocacy groups, and over 200 industry organizations will also contribute perspectives on enhancing healthcare delivery across borders.
"If we are to bridge gaps, drive progress, and shape policies that improve patient outcomes, we must achieve harmonization among stakeholders from every sector of the healthcare ecosystem," said Ania Mitan, DIA's Senior Vice President and Managing Director for Europe, the Middle East, Africa, and India (EMEAI). "DIA Europe 2025 creates opportunities for that to happen by providing an environment where meaningful solutions emerge from diverse perspectives and shared expertise."
Two healthcare leaders will deliver keynote presentations on how technology and patient care intersect to streamline treatments. Dr. Peiling Yap, Chief Scientist at HealthAI, will share strategies for implementing responsible AI standards that promote equitable, sustainable healthcare solutions. Simon Rasalingham, CEO and Chairman of behold.ai, will demonstrate how emerging diagnostic technologies can transform patient outcomes through early detection and improved treatment pathways.
The conference's signature DIAmond sessions will address key developments in European healthcare policy. During the EU Regulatory Town Hall, Emer Cooke, Executive Director of the EMA, will join María Jesús Lamas Díaz, Executive Director of the Spanish Agency for Medicines and Medical Devices (AEMPS), and Steffen Thirstrup, the EMA's Chief Medical Officer, for in-depth discussions on EU policy changes. Additional sessions will feature speakers from Amgen, AstraZeneca, Bayer, GSK, MSD, Roche, Sanofi, and Novartis, among others, and focus on frameworks for the global digitalization of medicine regulation, establishing sustainability standards, strengthening patient engagement practices, and advancing European healthcare initiatives.
DIA Europe 2025 will also introduce targeted programs to drive innovation and inclusion in healthcare. A startup accelerator on March 18 will connect emerging companies with regulatory authorities to accelerate development pathways. Interactive DIAlogue sessions will explore sustainable partnerships and develop strategies for including underserved populations in clinical trials.
To register or view the conference program, visit https://www.diaglobal.org/Flagship/DIA-Europe-2025. Media members can request credentials by emailing diaglobal@gregoryfca.com.
About DIA
DIA is a leading global non-profit life science membership association that drives collaboration in drug, device, and diagnostics development in pursuit of a healthier world. Founded in 1964 with headquarters in Washington, D.C., and offices in Europe and Asia, DIA provides unparalleled networking opportunities, educational resources, scientific research publications, and professional development programs to members in more than 80 countries.
Learn more at DIAglobal.org, and connect with DIA on LinkedIn, Facebook, X (Twitter), and Instagram.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250220566300/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 202525.4.2025 14:00:00 CEST | Press release
Incyte (Nasdaq:INCY) today announced that the Company will present new early-stage data from its oncology portfolio at the American Association of Cancer Research (AACR) Annual Meeting 2025 in Chicago, IL, from April 25–30. “At AACR we will be presenting data from early-stage programs across our oncology portfolio, including for patients with myeloproliferative neoplasms, ovarian cancer and other solid tumors,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. “These data will guide our approach as we advance our pipeline and seek to transform the treatment landscape for patients with cancer and myeloproliferative neoplasms.” Abstracts accepted for presentation at AACR include: Mini Symposium INCB177054 INCB177054: A Novel, Potent, Orally Bioavailable DGKα/ζ Dual Inhibitor Enhances T-Cell Function and Demonstrates Potent Antitumor Activity (Session Title: Novel Antitumor Agents. April 28, 4:50 p.m. – 5:05 p.m. ET (3:50 p.m. – 4:05 p.m. CT). Abstract #
SLB Announces First-Quarter 2025 Results; Remains Committed to Return a Minimum of $4 Billion to Shareholders in 202525.4.2025 12:50:00 CEST | Press release
Revenue of $8.49 billion decreased 3% year on year GAAP EPS of $0.58 decreased 22% year on year EPS, excluding charges and credits, of $0.72 decreased 4% year on year Net income attributable to SLB of $797 million decreased 25% year on year Adjusted EBITDA of $2.02 billion decreased 2% year on year Cash flow from operations of $660 million increased $333 million year on year Board approved quarterly cash dividend of $0.285 per share SLB (NYSE: SLB) today announced results for the first-quarter 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250423635499/en/ The exterior of the SLB headquarters in Houston, Texas. First-Quarter Results (Stated in millions, except per share amounts) Three Months EndedChange Mar. 31, 2025 Dec. 31, 2024 Mar. 31, 2024 Sequential Year-on-year Revenue $8,490 $9,284 $8,707 -9% -3% Income before taxes - GAAP basis $1,063 $1,387 $1,357 -23% -22% Income before taxes margin - GAAP basis 12.5% 14.9%
Corona, The World’s Most Valuable Beer Brand1, Announces Its 100-Year Anniversary with Global Celebration25.4.2025 10:00:00 CEST | Press release
Brand Invites The World to Join the Celebration with Experiences at the Most Epic Beaches on EarthGlobal “Corona 100” Platform Launches with a Legendary Concert at Copacabana Beach, Featuring One of the World’s Top Musical Artists with Millions in Attendance Today, Corona proudly celebrates its 100-year anniversary, a remarkable milestone for the iconic brand that has been synonymous with the beach and enjoyed by consumers worldwide for the past century. Since 1925, Corona has cultivated a deep association with the beach; fully embodying a lifestyle connected to nature and relaxation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425804516/en/ Corona 100 This Is Living Since 1925 In honor of the occasion, Corona invites everyone to live their “beach side” – a.k.a. their best side – at top-tier beach locations across the globe. The Corona 100 platform includes a film highlighting 100 years of beach culture, a definitive l
Ant Group Unveils New Recruitment Initiative for Top AI Talents, Ramping Up AI Innovation Efforts25.4.2025 09:28:00 CEST | Press release
Ant Group today unveiled Plan A, a new recruitment initiative to attract top artificial intelligence researchers, reinforcing its commitment to accelerating AI research and development under the “AI First” corporate strategy. Operating within the framework of Ant Star—Ant Group’s year-round campus recruitment program—Plan A specifically targets AI talents who are ambitious, adaptable, altruistic, and analytical. Outstanding graduates from universities worldwide with STEM majors are encouraged to apply for Plan A. Relevant fields include computer science, software engineering, artificial intelligence, cybersecurity, information and telecommunication engineering, mathematics, statistics, and other emerging interdisciplinary areas. To better foster the development of technological innovators in this new AI era, Plan A offers candidates comprehensive support and resources, including unrestricted access to AI hardware and tailored career paths that allow for significant research freedom. Ad
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom